What Should Patients Know about Antiphospholipid Antibodies and Antiphospholipid Syndrome? View Full Text


Ontology type: schema:Chapter     


Chapter Info

DATE

2012-03-20

AUTHORS

Doruk Erkan , Lindsay Lally , Michael D. Lockshin

ABSTRACT

Antiphospholipid syndrome (APS) is a systemic autoimmune disorder in which the immune system makes antibodies (antiphospholipid antibodies or aPL) that increase the risk to form blood clots. The most commonly used tests to detect aPL are Lupus Anticoagulant test, Anticardiolipin Antibody Test, and Anti-Beta-2-gylycoprotein-I Test. Among the various manifestations of APS, the most common clinical problems are blood clots in the veins of the legs, strokes, and miscarriages. Antiphospholipid antibodies can occur in otherwise healthy individuals or in patients with other autoimmune disorders such as systemic lupus erythematosus (SLE). Having a positive aPL test does not mean the person has APS; 30–40% of SLE patients may have aPL, but only a small percentage develop APS. For all aPL-positive patients with or without SLE, whether or not they have had a blood clot in the past, the first essential step in the management is understanding the risk of thrombosis and eliminating reversible risk factors known to increase risk of clotting. Further management of aPL-positive patients depends on the individual patient, his or her aPL-related clinical manifestations, and additional medical conditions. More... »

PAGES

295-309

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/978-1-4614-3194-7_20

DOI

http://dx.doi.org/10.1007/978-1-4614-3194-7_20

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1051665488


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1107", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Immunology", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "The Barbara Volcker Center for Women and Rheumatic Diseases, Hospital for Special Surgery, Weill Cornell Medical College of Cornell University, 535 E70th Street, 10021, New York, NY, USA", 
          "id": "http://www.grid.ac/institutes/grid.5386.8", 
          "name": [
            "The Barbara Volcker Center for Women and Rheumatic Diseases, Hospital for Special Surgery, Weill Cornell Medical College of Cornell University, 535 E70th Street, 10021, New York, NY, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Erkan", 
        "givenName": "Doruk", 
        "id": "sg:person.0706272321.25", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0706272321.25"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Rheumatology, Hospital for Special Surgery, New York, NY, USA", 
          "id": "http://www.grid.ac/institutes/grid.239915.5", 
          "name": [
            "Department of Rheumatology, Hospital for Special Surgery, New York, NY, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Lally", 
        "givenName": "Lindsay", 
        "id": "sg:person.01353036251.11", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01353036251.11"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "The Barbara Volcker Center for Women and Rheumatic Diseases, Hospital for Special Surgery, Weill Cornell Medical College of Cornell University, 535 E70th Street, 10021, New York, NY, USA", 
          "id": "http://www.grid.ac/institutes/grid.5386.8", 
          "name": [
            "The Barbara Volcker Center for Women and Rheumatic Diseases, Hospital for Special Surgery, Weill Cornell Medical College of Cornell University, 535 E70th Street, 10021, New York, NY, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Lockshin", 
        "givenName": "Michael D.", 
        "id": "sg:person.01215046705.41", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01215046705.41"
        ], 
        "type": "Person"
      }
    ], 
    "datePublished": "2012-03-20", 
    "datePublishedReg": "2012-03-20", 
    "description": "Antiphospholipid syndrome (APS) is a systemic autoimmune disorder in which the immune system makes antibodies (antiphospholipid antibodies or aPL) that increase the risk to form blood clots. The most commonly used tests to detect aPL are Lupus Anticoagulant test, Anticardiolipin Antibody Test, and Anti-Beta-2-gylycoprotein-I Test. Among the various manifestations of APS, the most common clinical problems are blood clots in the veins of the legs, strokes, and miscarriages. Antiphospholipid antibodies can occur in otherwise healthy individuals or in patients with other autoimmune disorders such as systemic lupus erythematosus (SLE). Having a positive aPL test does not mean the person has APS; 30\u201340% of SLE patients may have aPL, but only a small percentage develop APS. For all aPL-positive patients with or without SLE, whether or not they have had a blood clot in the past, the first essential step in the management is understanding the risk of thrombosis and eliminating reversible risk factors known to increase risk of clotting. Further management of aPL-positive patients depends on the individual patient, his or her aPL-related clinical manifestations, and additional medical conditions.", 
    "editor": [
      {
        "familyName": "Erkan", 
        "givenName": "Doruk", 
        "type": "Person"
      }, 
      {
        "familyName": "Pierangeli", 
        "givenName": "Silvia S.", 
        "type": "Person"
      }
    ], 
    "genre": "chapter", 
    "id": "sg:pub.10.1007/978-1-4614-3194-7_20", 
    "inLanguage": "en", 
    "isAccessibleForFree": false, 
    "isPartOf": {
      "isbn": [
        "978-1-4614-3193-0", 
        "978-1-4614-3194-7"
      ], 
      "name": "Antiphospholipid Syndrome", 
      "type": "Book"
    }, 
    "keywords": [
      "systemic lupus erythematosus", 
      "aPL-positive patients", 
      "antiphospholipid syndrome", 
      "blood clots", 
      "antiphospholipid antibodies", 
      "autoimmune disorders", 
      "aPL-related clinical manifestations", 
      "manifestations of APS", 
      "positive aPL test", 
      "reversible risk factors", 
      "systemic autoimmune disorders", 
      "lupus anticoagulant test", 
      "common clinical problem", 
      "additional medical conditions", 
      "risk of thrombosis", 
      "anticardiolipin antibody test", 
      "SLE patients", 
      "lupus erythematosus", 
      "clinical manifestations", 
      "risk factors", 
      "further management", 
      "aPL tests", 
      "medical conditions", 
      "individual patients", 
      "antibody test", 
      "clinical problem", 
      "healthy individuals", 
      "patients", 
      "immune system", 
      "clots", 
      "antibodies", 
      "syndrome", 
      "risk", 
      "disorders", 
      "manifestations", 
      "small percentage", 
      "APL", 
      "erythematosus", 
      "thrombosis", 
      "miscarriage", 
      "stroke", 
      "first essential step", 
      "test", 
      "vein", 
      "management", 
      "leg", 
      "persons", 
      "percentage", 
      "individuals", 
      "factors", 
      "essential step", 
      "conditions", 
      "system", 
      "step", 
      "past", 
      "problem", 
      "Anticoagulant test", 
      "Anti-Beta-2-gylycoprotein"
    ], 
    "name": "What Should Patients Know about Antiphospholipid Antibodies and Antiphospholipid Syndrome?", 
    "pagination": "295-309", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1051665488"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/978-1-4614-3194-7_20"
        ]
      }
    ], 
    "publisher": {
      "name": "Springer Nature", 
      "type": "Organisation"
    }, 
    "sameAs": [
      "https://doi.org/10.1007/978-1-4614-3194-7_20", 
      "https://app.dimensions.ai/details/publication/pub.1051665488"
    ], 
    "sdDataset": "chapters", 
    "sdDatePublished": "2021-11-01T18:59", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20211101/entities/gbq_results/chapter/chapter_402.jsonl", 
    "type": "Chapter", 
    "url": "https://doi.org/10.1007/978-1-4614-3194-7_20"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/978-1-4614-3194-7_20'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/978-1-4614-3194-7_20'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/978-1-4614-3194-7_20'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/978-1-4614-3194-7_20'


 

This table displays all metadata directly associated to this object as RDF triples.

140 TRIPLES      23 PREDICATES      83 URIs      76 LITERALS      7 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/978-1-4614-3194-7_20 schema:about anzsrc-for:11
2 anzsrc-for:1107
3 schema:author N63b2e56067b64d6389d84cf6c021047f
4 schema:datePublished 2012-03-20
5 schema:datePublishedReg 2012-03-20
6 schema:description Antiphospholipid syndrome (APS) is a systemic autoimmune disorder in which the immune system makes antibodies (antiphospholipid antibodies or aPL) that increase the risk to form blood clots. The most commonly used tests to detect aPL are Lupus Anticoagulant test, Anticardiolipin Antibody Test, and Anti-Beta-2-gylycoprotein-I Test. Among the various manifestations of APS, the most common clinical problems are blood clots in the veins of the legs, strokes, and miscarriages. Antiphospholipid antibodies can occur in otherwise healthy individuals or in patients with other autoimmune disorders such as systemic lupus erythematosus (SLE). Having a positive aPL test does not mean the person has APS; 30–40% of SLE patients may have aPL, but only a small percentage develop APS. For all aPL-positive patients with or without SLE, whether or not they have had a blood clot in the past, the first essential step in the management is understanding the risk of thrombosis and eliminating reversible risk factors known to increase risk of clotting. Further management of aPL-positive patients depends on the individual patient, his or her aPL-related clinical manifestations, and additional medical conditions.
7 schema:editor N7a9b56d9280e4d75928bea1b6f4aeb48
8 schema:genre chapter
9 schema:inLanguage en
10 schema:isAccessibleForFree false
11 schema:isPartOf Nb4142bddc3a4413a9f239bb025047c72
12 schema:keywords APL
13 Anti-Beta-2-gylycoprotein
14 Anticoagulant test
15 SLE patients
16 aPL tests
17 aPL-positive patients
18 aPL-related clinical manifestations
19 additional medical conditions
20 antibodies
21 antibody test
22 anticardiolipin antibody test
23 antiphospholipid antibodies
24 antiphospholipid syndrome
25 autoimmune disorders
26 blood clots
27 clinical manifestations
28 clinical problem
29 clots
30 common clinical problem
31 conditions
32 disorders
33 erythematosus
34 essential step
35 factors
36 first essential step
37 further management
38 healthy individuals
39 immune system
40 individual patients
41 individuals
42 leg
43 lupus anticoagulant test
44 lupus erythematosus
45 management
46 manifestations
47 manifestations of APS
48 medical conditions
49 miscarriage
50 past
51 patients
52 percentage
53 persons
54 positive aPL test
55 problem
56 reversible risk factors
57 risk
58 risk factors
59 risk of thrombosis
60 small percentage
61 step
62 stroke
63 syndrome
64 system
65 systemic autoimmune disorders
66 systemic lupus erythematosus
67 test
68 thrombosis
69 vein
70 schema:name What Should Patients Know about Antiphospholipid Antibodies and Antiphospholipid Syndrome?
71 schema:pagination 295-309
72 schema:productId N17964f035eb74cf3bb758f3a46407e85
73 N39b28dc2d7d74f80a391206aa3e4f924
74 schema:publisher N473806904ce145dd8e40df01a033c21b
75 schema:sameAs https://app.dimensions.ai/details/publication/pub.1051665488
76 https://doi.org/10.1007/978-1-4614-3194-7_20
77 schema:sdDatePublished 2021-11-01T18:59
78 schema:sdLicense https://scigraph.springernature.com/explorer/license/
79 schema:sdPublisher N414b1dabb5f84aceb211fca0894a79fe
80 schema:url https://doi.org/10.1007/978-1-4614-3194-7_20
81 sgo:license sg:explorer/license/
82 sgo:sdDataset chapters
83 rdf:type schema:Chapter
84 N17964f035eb74cf3bb758f3a46407e85 schema:name doi
85 schema:value 10.1007/978-1-4614-3194-7_20
86 rdf:type schema:PropertyValue
87 N35d47c19ab644f6b9d98819c880da2a7 rdf:first sg:person.01353036251.11
88 rdf:rest N386f76a8f0cc49c1a345029b761552e4
89 N386f76a8f0cc49c1a345029b761552e4 rdf:first sg:person.01215046705.41
90 rdf:rest rdf:nil
91 N39b28dc2d7d74f80a391206aa3e4f924 schema:name dimensions_id
92 schema:value pub.1051665488
93 rdf:type schema:PropertyValue
94 N414b1dabb5f84aceb211fca0894a79fe schema:name Springer Nature - SN SciGraph project
95 rdf:type schema:Organization
96 N450a973c223d48d693bb55c91eeb5234 schema:familyName Pierangeli
97 schema:givenName Silvia S.
98 rdf:type schema:Person
99 N473806904ce145dd8e40df01a033c21b schema:name Springer Nature
100 rdf:type schema:Organisation
101 N4821ecfb9be34a9cb0e46a0220b9e0e0 schema:familyName Erkan
102 schema:givenName Doruk
103 rdf:type schema:Person
104 N63b2e56067b64d6389d84cf6c021047f rdf:first sg:person.0706272321.25
105 rdf:rest N35d47c19ab644f6b9d98819c880da2a7
106 N7a9b56d9280e4d75928bea1b6f4aeb48 rdf:first N4821ecfb9be34a9cb0e46a0220b9e0e0
107 rdf:rest Nc7d2be9e1ea345b7a9f04c3d39ef5610
108 Nb4142bddc3a4413a9f239bb025047c72 schema:isbn 978-1-4614-3193-0
109 978-1-4614-3194-7
110 schema:name Antiphospholipid Syndrome
111 rdf:type schema:Book
112 Nc7d2be9e1ea345b7a9f04c3d39ef5610 rdf:first N450a973c223d48d693bb55c91eeb5234
113 rdf:rest rdf:nil
114 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
115 schema:name Medical and Health Sciences
116 rdf:type schema:DefinedTerm
117 anzsrc-for:1107 schema:inDefinedTermSet anzsrc-for:
118 schema:name Immunology
119 rdf:type schema:DefinedTerm
120 sg:person.01215046705.41 schema:affiliation grid-institutes:grid.5386.8
121 schema:familyName Lockshin
122 schema:givenName Michael D.
123 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01215046705.41
124 rdf:type schema:Person
125 sg:person.01353036251.11 schema:affiliation grid-institutes:grid.239915.5
126 schema:familyName Lally
127 schema:givenName Lindsay
128 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01353036251.11
129 rdf:type schema:Person
130 sg:person.0706272321.25 schema:affiliation grid-institutes:grid.5386.8
131 schema:familyName Erkan
132 schema:givenName Doruk
133 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0706272321.25
134 rdf:type schema:Person
135 grid-institutes:grid.239915.5 schema:alternateName Department of Rheumatology, Hospital for Special Surgery, New York, NY, USA
136 schema:name Department of Rheumatology, Hospital for Special Surgery, New York, NY, USA
137 rdf:type schema:Organization
138 grid-institutes:grid.5386.8 schema:alternateName The Barbara Volcker Center for Women and Rheumatic Diseases, Hospital for Special Surgery, Weill Cornell Medical College of Cornell University, 535 E70th Street, 10021, New York, NY, USA
139 schema:name The Barbara Volcker Center for Women and Rheumatic Diseases, Hospital for Special Surgery, Weill Cornell Medical College of Cornell University, 535 E70th Street, 10021, New York, NY, USA
140 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...